Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000020.xml
CC BY-NC-ND 4.0 · Geburtshilfe Frauenheilkd 2024; 84(02): 130-143
DOI: 10.1055/a-2201-2680
DOI: 10.1055/a-2201-2680
GebFra Science
Statement/Stellungnahme
Management of Rheumatic Diseases During Pregnancy and Breastfeeding
Position Paper of the Working Group for Obstetrics and Prenatal Medicine in the German Society for Gynecology and Obstetrics e. V. (AGG – Section Maternal Diseases in Pregnancy) Article in several languages: English | deutsch
Abstract
Purpose These recommendations issued by the AGG (Section Maternal Diseases in Pregnancy) were developed as a rapid orientation on maternal rheumatic diseases for counselling and disease management in pregnancy and breastfeeding.
Methods The standard literature, consensus and position papers, guidelines and recommendations by other specialist associations were evaluated by a task force of the Section and summarized in these recommendations following a joint consensus process.
Recommendations This paper provides an orientating overview of the physiology, pathophysiology and definitions of rheumatic diseases which is relevant for gynecologists and obstetricians. The recommendations focus on the maternal, fetal and neonatal diagnostic workup in cases with underlying maternal rheumatic disease.
Key words
rheumatism - pregnancy - lupus erythematosus - antiphospholipid antibodies - arthritis - vasculitisPublication History
Received: 10 August 2023
Accepted after revision: 23 October 2023
Article published online:
08 February 2024
© 2024. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commecial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)
Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany
-
References/Literatur
- 1 Arbuckle MR, McClain MT, Rubertone MV. et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med 2003; 349: 1526-1533 DOI: 10.1056/NEJMoa021933.
- 2 Andreoli L, Bertsias GK, Agmon-Levin N. et al. EULAR recommendations for womenʼs health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome. Ann Rheum Dis 2017; 76: 476-485 DOI: 10.1136/annrheumdis-2016-209770.
- 3 Tektonidou MG, Andreoli L, Limper M. et al. EULAR recommendations for the management of antiphospholipid syndrome in adults. Ann Rheum Dis 2019; 78: 1296-1304 DOI: 10.1136/annrheumdis-2019-215213.
- 4 Götestam Skorpen C, Hoeltzenbein M, Tincani A. et al. The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Ann Rheum Dis 2016; 75: 795-810 DOI: 10.1136/annrheumdis-2015-208840.
- 5 Sammaritano LR, Bermas BL, Chakravarty EE. et al. 2020 American College of Rheumatology Guideline for the Management of Reproductive Health in Rheumatic and Musculoskeletal Diseases. Arthritis Rheumatol 2020; 72: 529-556 DOI: 10.1002/art.41191.
- 6 Sciascia S, Radin M, Cecchi I. et al. 16th International congress on antiphospholipid antibodies task force report on clinical manifestations of antiphospholipid syndrome. Lupus 2021; 30: 1314-1326 DOI: 10.1177/09612033211020361.
- 7 Gordon C, Amissah-Arthur MB, Gayed M. et al. The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults: Executive Summary. Rheumatology (Oxford) 2018; 57: 14-18 DOI: 10.1093/rheumatology/kex291.
- 8 Fischer-Betz R, Haase I. [Pregnancy with lupus erythematosus-an update]. Z Rheumatol 2020; 79: 359-366 DOI: 10.1007/s00393-020-00772-9.
- 9 Kwok LW, Tam LS, Zhu T. et al. Predictors of maternal and fetal outcomes in pregnancies of patients with systemic lupus erythematosus. Lupus 2011; 20: 829-836 DOI: 10.1177/0961203310397967.
- 10 Clowse ME, Magder LS, Petri M. The clinical utility of measuring complement and anti-dsDNA antibodies during pregnancy in patients with systemic lupus erythematosus. J Rheumatol 2011; 38: 1012-1016 DOI: 10.3899/jrheum.100746.
- 11 Buyon JP, Kim MY, Guerra MM. et al. Predictors of Pregnancy Outcomes in Patients With Lupus: A Cohort Study. Ann Intern Med 2015; 163: 153-163 DOI: 10.7326/M14-2235.
- 12 Buyon JP, Kim MY, Guerra MM. et al. Kidney Outcomes and Risk Factors for Nephritis (Flare/De Novo) in a Multiethnic Cohort of Pregnant Patients with Lupus. Clin J Am Soc Nephrol 2017; 12: 940-946 DOI: 10.2215/CJN.11431116.
- 13 Rodrigues BC, Lacerda MI, Ramires de Jesus GR. et al. The impact of different classes of lupus nephritis on maternal and fetal outcomes: a cohort study of 147 pregnancies. Lupus 2019; 28: 492-500 DOI: 10.1177/0961203319829825.
- 14 Smyth A, Oliveira GH, Lahr BD. et al. A systematic review and meta-analysis of pregnancy outcomes in patients with systemic lupus erythematosus and lupus nephritis. Clin J Am Soc Nephrol 2010; 5: 2060-2068 DOI: 10.2215/CJN.00240110.
- 15 Dong Y, Yuan F, Dai Z. et al. Preeclampsia in systemic lupus erythematosus pregnancy: a systematic review and meta-analysis. Clin Rheumatol 2020; 39: 319-325 DOI: 10.1007/s10067-019-04823-8.
- 16 Bandoli G, Singh N, Strouse J. et al. Mediation of Adverse Pregnancy Outcomes in Autoimmune Conditions by Pregnancy Complications: A Mediation Analysis of Autoimmune Conditions and Adverse Pregnancy Outcomes. Arthritis Care Res (Hoboken) 2020; 72: 256-264 DOI: 10.1002/acr.24037.
- 17 Skorpen CG, Lydersen S, Gilboe IM. et al. Influence of disease activity and medications on offspring birth weight, pre-eclampsia and preterm birth in systemic lupus erythematosus: a population-based study. Ann Rheum Dis 2018; 77: 264-269 DOI: 10.1136/annrheumdis-2017-211641.
- 18 Koh JH, Ko HS, Kwok SK. et al. Hydroxychloroquine and pregnancy on lupus flares in Korean patients with systemic lupus erythematosus. Lupus 2015; 24: 210-217 DOI: 10.1177/0961203314555352.
- 19 Seo MR, Chae J, Kim YM. et al. Hydroxychloroquine treatment during pregnancy in lupus patients is associated with lower risk of preeclampsia. Lupus 2019; 28: 722-730 DOI: 10.1177/0961203319843343.
- 20 Clowse MEB, Eudy AM, Balevic S. et al. Hydroxychloroquine in the pregnancies of women with lupus: a meta-analysis of individual participant data. Lupus Sci Med 2022; DOI: 10.1136/lupus-2021-000651.
- 21 Leroux M, Desveaux C, Parcevaux M. et al. Impact of hydroxychloroquine on preterm delivery and intrauterine growth restriction in pregnant women with systemic lupus erythematosus: a descriptive cohort study. Lupus 2015; 24: 1384-1391 DOI: 10.1177/0961203315591027.
- 22 Rolnik DL, Wright D, Poon LC. et al. Aspirin versus Placebo in Pregnancies at High Risk for Preterm Preeclampsia. N Engl J Med 2017; 377: 613-622 DOI: 10.1056/NEJMoa1704559.
- 23 Roberge S, Nicolaides K, Demers S. et al. The role of aspirin dose on the prevention of preeclampsia and fetal growth restriction: systematic review and meta-analysis. Am J Obstet Gynecol 2017; 216: 110-120.e6 DOI: 10.1016/j.ajog.2016.09.076.
- 24 Ayala DE, Ucieda R, Hermida RC. Chronotherapy with low-dose aspirin for prevention of complications in pregnancy. Chronobiol Int 2013; 30: 260-279 DOI: 10.3109/07420528.2012.717455.
- 25 Ruiz-Irastorza G, Khamashta MA. Evaluation of systemic lupus erythematosus activity during pregnancy. Lupus 2004; 13: 679-682 DOI: 10.1191/0961203304lu1099oa.
- 26 Yee CS, Khamashta M, Akil M. et al. The BILAG2004-Pregnancy Index is a valid disease activity outcome measure for pregnant SLE patients. Rheumatol Adv Pract 2022; 6: rkac081 DOI: 10.1093/rap/rkac081.
- 27 Lockshin MD, Kim M, Laskin CA. et al. Prediction of adverse pregnancy outcome by the presence of lupus anticoagulant, but not anticardiolipin antibody, in patients with antiphospholipid antibodies. Arthritis Rheum 2012; 64: 2311-2318 DOI: 10.1002/art.34402.
- 28 Miyakis S, Lockshin MD, Atsumi T. et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4: 295-306 DOI: 10.1111/j.1538-7836.2006.01753.x.
- 29 Garcia D, Erkan D. Diagnosis and Management of the Antiphospholipid Syndrome. N Engl J Med 2018; 378: 2010-2021 DOI: 10.1056/NEJMra1705454.
- 30 Buyon JP, Winchester RJ, Slade SG. et al. Identification of mothers at risk for congenital heart block and other neonatal lupus syndromes in their children. Comparison of enzyme-linked immunosorbent assay and immunoblot for measurement of anti-SS-A/Ro and anti-SS-B/La antibodies. Arthritis Rheum 1993; 36: 1263-1273 DOI: 10.1002/art.1780360911.
- 31 Jaeggi E, Laskin C, Hamilton R. et al. The importance of the level of maternal anti-Ro/SSA antibodies as a prognostic marker of the development of cardiac neonatal lupus erythematosus a prospective study of 186 antibody-exposed fetuses and infants. J Am Coll Cardiol 2010; 55: 2778-2784 DOI: 10.1016/j.jacc.2010.02.042.
- 32 Brito-Zeron P, Izmirly PM, Ramos-Casals M. et al. The clinical spectrum of autoimmune congenital heart block. Nat Rev Rheumatol 2015; 11: 301-312 DOI: 10.1038/nrrheum.2015.29.
- 33 Brucato A, Cimaz R, Caporali R. et al. Pregnancy outcomes in patients with autoimmune diseases and anti-Ro/SSA antibodies. Clin Rev Allergy Immunol 2011; 40: 27-41 DOI: 10.1007/s12016-009-8190-6.
- 34 Cuneo BF, Sonesson SE, Levasseur S. et al. Home Monitoring for Fetal Heart Rhythm During Anti-Ro Pregnancies. J Am Coll Cardiol 2018; 72: 1940-1951 DOI: 10.1016/j.jacc.2018.07.076.
- 35 Friedman DM, Kim MY, Copel JA. et al. Utility of cardiac monitoring in fetuses at risk for congenital heart block: the PR Interval and Dexamethasone Evaluation (PRIDE) prospective study. Circulation 2008; 117: 485-493 DOI: 10.1161/CIRCULATIONAHA.107.707661.
- 36 Izmirly PM, Costedoat-Chalumeau N, Pisoni CN. et al. Maternal use of hydroxychloroquine is associated with a reduced risk of recurrent anti-SSA/Ro-antibody-associated cardiac manifestations of neonatal lupus. Circulation 2012; 126: 76-82 DOI: 10.1161/CIRCULATIONAHA.111.089268.
- 37 Cimaz R, Spence DL, Hornberger L. et al. Incidence and spectrum of neonatal lupus erythematosus: a prospective study of infants born to mothers with anti-Ro autoantibodies. J Pediatr 2003; 142: 678-683 DOI: 10.1067/mpd.2003.233.
- 38 Boros CA, Spence D, Blaser S. et al. Hydrocephalus and macrocephaly: new manifestations of neonatal lupus erythematosus. Arthritis Rheum 2007; 57: 261-266 DOI: 10.1002/art.22543.
- 39 Levy R, Briggs L, Silverman E. et al. Cutaneous sequelae in neonatal lupus: A retrospective cohort study. J Am Acad Dermatol 2020; 83: 440-446 DOI: 10.1016/j.jaad.2019.09.083.
- 40 Dima A, Jurcut C, Chasset F. et al. Hydroxychloroquine in systemic lupus erythematosus: overview of current knowledge. Ther Adv Musculoskelet Dis 2022; 14 DOI: 10.1177/1759720X211073001.
- 41 Izmirly P, Kim M, Friedman DM. et al. Hydroxychloroquine to Prevent Recurrent Congenital Heart Block in Fetuses of Anti-SSA/Ro-Positive Mothers. J Am Coll Cardiol 2020; 76: 292-302 DOI: 10.1016/j.jacc.2020.05.045.
- 42 Eudy AM, McDaniel G, Clowse MEB. Pregnancy in rheumatoid arthritis: a retrospective study. Clin Rheumatol 2018; 37: 789-794 DOI: 10.1007/s10067-017-3939-4.
- 43 Ruiz-Irastorza G, Lima F, Alves J. et al. Increased rate of lupus flare during pregnancy and the puerperium: a prospective study of 78 pregnancies. Br J Rheumatol 1996; 35: 133-138 DOI: 10.1093/rheumatology/35.2.133.
- 44 Barrett JH, Brennan P, Fiddler M. et al. Does rheumatoid arthritis remit during pregnancy and relapse postpartum? Results from a nationwide study in the United Kingdom performed prospectively from late pregnancy. Arthritis Rheum 1999; 42: 1219-1227 DOI: 10.1002/1529-0131(199906)42:6<1219::AID-ANR19>3.0.CO;2-G.
- 45 [Anonymous] Reducing the Risk of Venous Thromboembolism during Pregnancy and the Puerperium – RCOG Green-top Guideline No. 37a. 2015. Accessed Decemver 22, 2023 at: https://www.rcog.org.uk/media/qejfhcaj/gtg-37a.pdf
- 46 Anderson JE, Held N, Wright K. Raynaudʼs phenomenon of the nipple: a treatable cause of painful breastfeeding. Pediatrics 2004; 113: e360-e364 DOI: 10.1542/peds.113.4.e360.
- 47 Barrett ME, Heller MM, Stone HF. et al. Raynaud phenomenon of the nipple in breastfeeding mothers: an underdiagnosed cause of nipple pain. JAMA Dermatol 2013; 149: 300-306 DOI: 10.1001/jamadermatol.2013.1560.
- 48 Anderson PO. Drug Treatment of Raynaudʼs Phenomenon of the Nipple. Breastfeed Med 2020; 15: 686-688 DOI: 10.1089/bfm.2020.0198.
- 49 Jethwa H, Lam S, Smith C. et al. Does Rheumatoid Arthritis Really Improve During Pregnancy? A Systematic Review and Metaanalysis. J Rheumatol 2019; 46: 245-250 DOI: 10.3899/jrheum.180226.
- 50 Huang W, Wu T, Jin T. et al. Maternal and fetal outcomes in pregnant women with rheumatoid arthritis: a systematic review and meta-analysis. Clin Rheumatol 2023; 42: 855-870 DOI: 10.1007/s10067-022-06436-0.
- 51 Eudy AM, McDaniel G, Clowse ME. Pregnancy outcomes, fertility, and family planning in women with psoriatic arthritis. Obstet Med 2020; 13: 70-75 DOI: 10.1177/1753495X18820463.
- 52 Giovannopoulou E, Gkasdaris G, Kapetanakis S. et al. Ankylosing Spondylitis and Pregnancy: A Literature Review. Curr Rheumatol Rev 2017; 13: 162-169 DOI: 10.2174/1573397113666170317114857.
- 53 Ghalandari N, Kemper E, Crijns IH. et al. Analysing cord blood levels of TNF inhibitors to validate the EULAR points to consider for TNF inhibitor use during pregnancy. Ann Rheum Dis 2022; 81: 402-405 DOI: 10.1136/annrheumdis-2021-221036.
- 54 Romanowska-Prochnicka K, Felis-Giemza A, Olesinska M. et al. The Role of TNF-alpha and Anti-TNF-alpha Agents during Preconception, Pregnancy, and Breastfeeding. Int J Mol Sci 2021; 22: 2922 DOI: 10.3390/ijms22062922.
- 55 Nielsen OH, Gubatan JM, Juhl CB. et al. Biologics for Inflammatory Bowel Disease and Their Safety in Pregnancy: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol 2022; 20: 74-87.e3 DOI: 10.1016/j.cgh.2020.09.021.
- 56 Tardif ML, Mahone M. Mixed connective tissue disease in pregnancy: A case series and systematic literature review. Obstet Med 2019; 12: 31-37 DOI: 10.1177/1753495X18793484.
- 57 Sims C, Clowse MEB. A comprehensive guide for managing the reproductive health of patients with vasculitis. Nat Rev Rheumatol 2022; 18: 711-723 DOI: 10.1038/s41584-022-00842-z.